Severe bronchiolitis profiling as the first step towards prevention of asthma.
Allergol Immunopathol (Madr)
; 51(3): 99-107, 2023.
Article
in English
| MEDLINE | ID: covidwho-2325362
ABSTRACT
Bronchiolitis is the most common respiratory infection leading to hospitalization and constitutes a significant healthcare burden. The two main viral agents causing bronchiolitis, respiratory syncytial virus (RSV) and rhinovirus (RV), have distinct cytopathic, immune response, and clinical characteristics. Different approaches have been suggested for subtyping bronchiolitis based on viral etiology, atopic status, transcriptome profiles in blood, airway metabolome, lipidomic data, and airway microbiota. The highest risk of asthma at school age has been in a subgroup of bronchiolitis characterized by older age, high prevalence of RV infection, previous breathing problems, and/or eczema. Regarding solely viral etiology, RV-bronchiolitis in infancy has been linked to a nearly three times higher risk of developing asthma than RSV-bronchiolitis. Although treatment with betamimetics and systemic corticosteroids has been found ineffective in bronchiolitis overall, it can be beneficial for infants with severe RV bronchiolitis. Thus, there is a need to develop a more individualized therapeutic approach for bronchiolitis and follow-up strategies for infants at higher risk of asthma in the future perspective.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Asthma
/
Bronchiolitis
/
Bronchiolitis, Viral
/
Respiratory Syncytial Virus, Human
/
Respiratory Syncytial Virus Infections
Type of study:
Cohort study
/
Etiology study
/
Observational study
/
Prognostic study
Limits:
Humans
/
Infant
Language:
English
Journal:
Allergol Immunopathol (Madr)
Year:
2023
Document Type:
Article
Affiliation country:
Aei.v51i3.788
Similar
MEDLINE
...
LILACS
LIS